ArticleNeurology2022

Author Response: Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease: Three-Year Outcomes From the PD-1101 Trial.

Chadwick W Christine et al.PubMed ↗Publisher ↗

No numbers read from the abstract.